Article

Good News for Cheese Lovers, Kill Cancer with Dairy Preservatives

Author(s):

Cheese contains a natural food preservative, nisin, which can destroy cancer cells.

Cheese contains a natural food preservative, nisin, which can destroy cancer cells.

A recent study published in the Journal of Antimicrobial Chemotherapy, the positive benefits of nisin — a colorless and tasteless powder that grows on brie, camembert, and cheddar cheese.

Previous studies found high doses of nisin could improve oral health when measured among foods at a quantity of 0.25 to 37.4mg. Meanwhile, the current study isolated and purified nisin, giving a dose of 800mg in the form of a milkshake to mice with neck tumors.

Yvonne Kapila, MD, professor at the University of Michigan School of Dentistry, and colleagues studied nisin in cancerous tumors and as an antimicrobial to combat diseases of the mouth.

After a 9-week period, the nisin treatment killed between 70-80% of the cancer cells.

The preservative was also shown to fight deadly bacteria like antibiotic-resistant MRSA and Kapila’s group observed experimental uses of nisin to treat 30 different types of cancer; infections of the skin, respiratory system, and abdomen; and oral health.

Despite promising results, the findings are limited and only in mice, so it’s too soon to tell whether nisin would react similarly in humans. The next immediate step for Kapila is to test nisin in a clinical setting.

“The application of nisin has advanced beyond its role as a food biopreservative. Current findings and other published data support nisin’s potential use to treat antibiotic resistant infections, periodontal disease, and cancer,” Kapila concluded in a news release.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards